Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: Concerns on the detection of doping with testosterone in treated hypogonadal athletes

Journal of Endocrinological Investigation

Volumn 32, Issue 5, 2009, Pages 445-453

  Di Luigi, L ^a   Sgro P ^a   Romanelli, F ^b   Mazzarino, M ^c   Donati, F ^c   Bragano M C ^c   Bianchini, S ^a   Fierro, V ^a   Casasco, M ^d   Botre F ^b,c   Lenzi, A ^b  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Italian National Olympic Committee   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Androgens; Doping; Hypogonadism; Sport; Testosterone

Indexed keywords

5BETA ANDROSTANE 3ALPHA,17BETA DIOL; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTERONE; EPITESTOSTERONE; ETIOCHOLANOLONE; GLUCURONIDE; TESTOSTERONE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHLETE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOPING; GAS CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERANDROGENISM; HYPOGONADISM; MALE; NORMAL HUMAN; OPEN STUDY; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL;

ADULT; ATHLETES; DOPING IN SPORTS; HORMONES; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; MALE; PLACEBOS; TESTOSTERONE; YOUNG ADULT;

EID: 70350341475     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03346484     Document Type: Article

References (43)

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91: 1995-2010. (Pubitemid 43854972)
2. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65: 275-281 (Pubitemid 44244915)
3. Isidori AM, Lenzi A. Testosterone replacement therapy: what we know is not yet enough. Mayo Clin Proc 2007, 82: 11-13 (Pubitemid 46036315)
4. Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol 2005, 4: 293-309. (Pubitemid 43126997)
5. Seftel AD. Male hypogonadism. Part I: Epidemiology of hypogonadism. Int J Impot Res 2006, 18: 115-120
6. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med 1996, 334: 707-714
7. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 2004, 4: 614-620
8. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006, 38: 644-651
9. Wood RI. Anabolic steroid: a fatal attraction? J Neuroendocrinol 2006, 18: 227-228
10. Di Luigi L, Romanelli F, Lenzi A. Androgenic-anabolic steroids abuse in males. J Endocrinol Invest 2005, 28 (Suppl): 81-84
11. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006, 5: 104-109
12. Aguilera R, Hatton CK, Catlin DH. Detection of epitestosterone doping by use isotope Mass Spectrometry. Clin Chem 2002, 48: 629-636 (Pubitemid 34261226)
13. Saudan C, Baume N, Robinson N, Avois L, Mangin P, Saugy M. Testosterone and doping control. Br J Sports Med (Suppl) 2006, 40: i21-4.
14. Seftel AD. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res 2006, 18: 223-228
15. Zitzmann M, Nieschlag E. Effects of androgen replacement on metabolism and physical performances in male hypogonadism. J Endocrinol Invest 2003, 26: 886-892 (Pubitemid 38049172)
16. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005, 63: 280-293 (Pubitemid 41233445)
17. Lombardo F, Sgrò P, Salacone P, et al. Androgens and fertility. J Endocrinol Invest 2005, 28 (Suppl): 51-55
18. Nakazawa R, Baba K, Nakano M, et al. Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism. Endocr J 2006, 53: 305-310 (Pubitemid 43988158)
19. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999, 84: 3469-3478 (Pubitemid 30645193)
20. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980, 51: 1335-1339 (Pubitemid 11199624)
21. Hubl W, Siebert W, Büchner M, Hering H. Die ausscheidung von testosteron, epitestosteron, und androstenedion vor und nach HCG-applikation bei normalen männerm und patienten mit primärem and sekundärem hypogonadismus. Endokrinologie 1971, 58: 62-74.
22. Kicman AT, Brooks RV, Collyer SC, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990, 24: 253-264
23. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol 1993, 44: 179-189 (Pubitemid 23072270)
24. Palonek E, Gottlieb C, Garle M, Björkhem I, Carlström K. Serum and urinary markers of exogenous testosterone administration. J Steroid Biochem Mol Biol 1995, 55: 121-127
25. Peng SH, Segura J, Farré M, González JC, de la Torre X. Plasma and urinary markers of oral testosterone undecanoate misuse. Steroids 2002, 67: 39-50. (Pubitemid 33112003)
26. Buiarelli F, Cartoni GP, Amendola L, Botrè F. Screening and confirmation analysis of anabolic agents in humans urine by gas chromatography-hybrid mass spectrometry (high resolution- time of flight). Anal Chim Acta 2001, 447: 75-88. (Pubitemid 33044599)
27. Di Luigi L, Guidetti L, Pigozzi F, et al. Acute amino acids supplementation enhances pituitary responsiveness in athletes. Med Sci Sports Exerc 1999, 31: 1748-1754 (Pubitemid 30012890)
28. Di Luigi L, Rossi C, Sgrò P, et al. Do non-steroidal anti-inflammatory drugs influence the steroid hormone milieu in male athletes? Int J Sports Med 2007, 28: 809-814
29. Sanders BK. Sex, drugs and sports: prostaglandins, epitestosterone and sexual development. Med Hypotheses 2007, 69: 829-835
30. Mazzarino M, Botrè F. A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids. Rapid Commun Mass Spectrom 2006, 20: 3465-3476 (Pubitemid 44763947)
31. Sodergard R, Backstrom T, Shanbag V, Cartensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982, 16: 801-810 (Pubitemid 13228095)
32. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666-3672 (Pubitemid 30645223)
33. Deslypere JP, Sayed A, Punjabi U, Verdonck L, Vermeulen A. Plasma 5α-androstane-3α,17β-diol and urinary 5α-androstane- 3α,17β-diol glucuronide, parameters of peripheral androgen action: a comparative study. J Clin Endocrinol Metab 1982, 54: 386-391
34. Donike M, Bärwald KR, Klostermann K, Schänzer W, Zimmerman J. Nachweis von exogenem Testosteron. In: Heck H, Hollmann W, Liesen H, Rost R, eds. Sport:Leistung und Gesundheit. Köln: Deutscher Ärzte Verlag, 1983, 293-298
35. Raynaud E, Audran M, Pages JC, et al. Determination of urinary testosterone end epitestosterone during pubertal development: a cross- sectional study in 141 normal male subjects. Clin Endocrinol (Oxf) 1993, 38: 353-359 (Pubitemid 23105066)
36. Dehennin L, Delgado A, Pérès G. Urinary profile of androgen metabolites at different stages of pubertal development in a population of sporting male subjects. Eur J Endocrinol 1994, 130: 53-59 (Pubitemid 24110433)
37. Tamm J, Volkwein U, Starcevic Z. The urinary excretion of epitestosterone, testosterone and androstenedione following intravenous infusions of high doses of steroids in human subjects. Steroids 1966, 8: 659-699
38. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparation. In: Nieschlag E, Behre HM, eds. Testosterone Action, Deficiency, Substitution. Cambridge: University Press. 2004, 115-135
39. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996, 335: 1-7. (Pubitemid 26230806)
40. Timón Andrada R, Maynar Mariño M, Muñoz Marín D, Olcina Camacho GJ, Caballero MJ, Maynar Mariño JI. Variations in urine excretion of steroid hormones after and acute session and after a 4-week programme of strength training. Eur J Appl Physiol 2007, 99: 65-71.
41. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekström L, Rane A. Doping test results dependent on genotype of uridine diphosphoglucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008, 93: 2500-2506 (Pubitemid 352008513)
42. Gooren LJ, Behre HM. Testosterone treatment of hypogonadal men participating in competitive sports. Andrologia 2008, 40: 195-199
43. Zhou Y, Du GH, Geng MY, Lu ZH. Rapid detection of anabolic steroids in urine by protein arrays. Int J Sports Med 2006, 27: 526-532 (Pubitemid 44047987)